

Dear Members of the Legislature,

I am against the passing of **LD 1847**, “An Act to Institute Testing and Tracking of Medical Use Cannabis and Cannabis Products.” While I understand the importance of safety and accountability in the medical cannabis program, this bill imposes unnecessary and harmful burdens on patients and caregivers across Maine.

**Why LD 1847 Should Be Opposed:**

- **Disproportionate Impact on Small Businesses:** The bill imposes burdensome regulations that larger, commercial dispensaries can absorb more easily, effectively disadvantaging small, local caregivers.
- **Threatens Patient Access and Choice:** By driving out small caregivers, the bill could reduce diversity in product options and limit access to personalized, compassionate care.
- **Unnecessary Overregulation:** Medical cannabis patients and providers already follow existing laws. Applying adult-use standards to medical use may be excessive and not medically appropriate.
- **Increased Costs Without Added Benefit:** The financial strain on caregivers will likely result in higher prices for patients, without a corresponding increase in safety or efficacy.
- **Potential for Market Consolidation:** The bill could lead to corporatization of the medical cannabis space, sidelining grassroots caregivers who have supported patients for years.

LD 1847, as written, would not make patients safer. Instead, it would undermine the core values of Maine’s medical cannabis program by favoring large, corporate interests over small providers and patient choice. If enacted, it will reduce access, increase costs, and limit the availability of effective medicine for those who need it most.

I urge you to reject this bill and instead support policies that protect and strengthen Maine’s compassionate, community-based medical cannabis system.

Sincerely,  
Vanessa Muskie  
Saco, Maine